In fact, it was under this paradigm that Olaparib (OLA, Lynparza, AZD-2281) reached U.S. Food and Drug Administration (FDA) approval to treat BRCA-1 mutated cancers (ucm572143, ucm592357, and NCT02987543). Here, BRCA1 is linked to cancer.